Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $30
Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $44 to $30.
Raymond James Maintains Outperform on Veracyte, Lowers Price Target to $30
Raymond James analyst Andrew Cooper maintains Veracyte (NASDAQ:VCYT) with a Outperform and lowers the price target from $34 to $30.
Veracyte Highlights New Consensus Data From Survey Of Leading Breast Cancer Oncologists In Europe Presented At European Society Of Medical Oncology
Veracyte, Inc. (NASDAQ:VCYT) announced today that new consensus data from a survey of leading breast cancer oncologists in Europe suggest the importance of gene expression profile (GEP) testing in guiding treatment
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Needham Maintains Buy on Veracyte, Lowers Price Target to $31
Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $35 to $31.
Veracyte Q4 EPS $(0.15) Beats $(0.16) Estimate, Sales $67.34M Beat $61.78M Estimate
Veracyte (NASDAQ:VCYT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 7.14 percent decrease over losses of $(0.14) per share from the same
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
Veracyte Says New Data Suggest Co’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment For Patients With Early-Stage Lung Cancer
Veracyte, Inc. (NASDAQ:VCYT) announced the publication of new data that suggest the company's Percepta Genomic Sequencing Classifier (GSC) can accelerate delivery of curative therapy for patients with high-risk lung
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.